Scribd Logo
Upload

Welcome to Scribd!

  • 353 views

    Emetogenic Potential of Antineoplastic Agents PDF

    Uploaded by

    alfox2000
    This document categorizes antineoplastic agents based on their emetogenic potential and risk of causing vomiting without antiemetics. It lists agents with high (>90%), moderate (30-90%), low (10-30%), and minimal (<10%) risk. High risk agents include certain drug combinations like doxorubicin and cyclophosphamide as well as single agents like cisplatin ≥50mg/m2 and cyclophosphamide >1,500mg/m2. Moderate risk agents include doxorubicin ≤60mg/m2 and methotrexate >50mg/m2 to <250mg/m2. Low risk agents include mercaptopurine and methotrexate

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd

    Emetogenic Potential of Antineoplastic Agents PDF

    Uploaded by

    alfox2000
    353 views1 page
    This document categorizes antineoplastic agents based on their emetogenic potential and risk of causing vomiting without antiemetics. It lists agents with high (>90%), moderate (30-90%), low (10-30%), and minimal (<10%) risk. High risk agents include certain drug combinations like doxorubicin and cyclophosphamide as well as single agents like cisplatin ≥50mg/m2 and cyclophosphamide >1,500mg/m2. Moderate risk agents include doxorubicin ≤60mg/m2 and methotrexate >50mg/m2 to <250mg/m2. Low risk agents include mercaptopurine and methotrexate

    Original Title

    Emetogenic Potential of Antineoplastic Agents.pdf

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    This document categorizes antineoplastic agents based on their emetogenic potential and risk of causing vomiting without antiemetics. It lists agents with high (>90%), moderate (30-90%), low (10-30%), and minimal (<10%) risk. High risk agents include certain drug combinations like doxorubicin and cyclophosphamide as well as single agents like cisplatin ≥50mg/m2 and cyclophosphamide >1,500mg/m2. Moderate risk agents include doxorubicin ≤60mg/m2 and methotrexate >50mg/m2 to <250mg/m2. Low risk agents include mercaptopurine and methotrexate

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    353 views1 page

    Emetogenic Potential of Antineoplastic Agents PDF

    Uploaded by

    alfox2000
    This document categorizes antineoplastic agents based on their emetogenic potential and risk of causing vomiting without antiemetics. It lists agents with high (>90%), moderate (30-90%), low (10-30%), and minimal (<10%) risk. High risk agents include certain drug combinations like doxorubicin and cyclophosphamide as well as single agents like cisplatin ≥50mg/m2 and cyclophosphamide >1,500mg/m2. Moderate risk agents include doxorubicin ≤60mg/m2 and methotrexate >50mg/m2 to <250mg/m2. Low risk agents include mercaptopurine and methotrexate

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    You are on page 1of 1

    EMETOGENIC POTENTIAL OF ANTINEOPLASTIC AGENTS

    High Risk (>90% frequency without antiemetics)


    AC combination: Doxorubicin (Adriamycin) or Epirubicin (Ellence) Cyclophosphamide (Cytoxan, Neosar) Altretamine (HMM, Hexalen) Carmustine (BCNU, BiCNU) 250mg/m2 Cisplatin (CDDP, Platinol, Platinol-AQ) 50mg/m2 Cyclophosphamide (CTX, Cytoxan, Neosar) 1,500mg/m2 Dacarbazine (DTIC, DTIC-Dome) Aldesleukin (IL-2, Proleukin) 1215 million units/m2 Amifostine (Ethyol) 300mg/m2 Arsenic trioxide (As2O3, Trisenox) Azacitidine (Vidaza) Bendamustine (Treanda) Busulfan (Busulfex) IV, oral 4mg/d Carboplatin (Paraplatin) Carmustine (BCNU, BiCNU) 250mg/m2 Cisplatin (CDDP, Platinol, Platinol-AQ) 50mg/m2 Clofarabine (Clolar) Cyclophosphamide (CTX, Cytoxan, Neosar) 1,500mg/m2 Cyclophosphamide (CTX) oral 100mg/m2/d Cytarabine (ARA-C, Cytosar-U) 200mg/m2 Dactinomycin (actinomycin D, Cosmegen) Daunorubicin (Cerubidine, Daunomycin) Aldesleukin (IL-2, Proleukin) 12 million units/m2 Amifostine (Ethoyl) 300mg Bexarotene (Targretin) Cabazitaxel (Jevtana) Capecitabine (Xeloda) oral Cetuximab (C225, Erbitux) Cyclophosphamide (CTX) oral 100mg/m2/d Cytarabine (ARA-C, Cytosar-U) 100200mg/m2 Docetaxel (Taxotere) Doxorubicin liposomal (Doxil) Eribulin (Halaven) Etoposide (VP-16, Etopophos, VePesid) IV Floxuridine Fludarabine (Fludara) oral Fluorouracil (5-FU) Alemtuzumab (Campath) Asparaginase (Elspar) Bevacizumab (Avastin) Bleomycin (Blenoxane) Bortezomib (Velcade) Busulfan (Busulfex) oral 4mg/d Cetuximab (Erbitux) Chlorambucil (Leukeran) oral Cladribine (2-CdA, Leustatin) Cytarabine (ARA-C, Cytosar-U) 100mg/m2 Dasatinib (Sprycel) Decitabine (Dacogen) Denileukin diftitox (Ontak) Dexrazoxane (Totect, Zinecard) Erlotinib (Tarceva) Everolimus (Afinitor, Zortress) Fludarabine (Fludara) IV Gefitinib (Iressa) Hydroxyurea (Hydrea) oral Imatinib (Gleevec) Interferon alpha (IFN-alfa, Intron A) 5 million units/m2 Ipilimumab (Yervoy) Lapatinib (Tykerb) Lenalidomide (Revlimid) Melphalan (L-PAM, Alkeran) low dose oral Doxorubicin (Adriamycin) >60mg/m2 Epirubicin (Ellence) >90mg/m2 Ifosfamide (Ifex) >10g/m2 Mechlorethamine (Mustargen) Procarbazine (Matulane) oral Streptozocin (Zanosar) Doxorubicin (Adriamycin) 60mg/m2 Epirubicin (Ellence) 90mg/m2 Estramustine (Emcyt) Etoposide (VP-16, VePesid) oral Idarubicin (Idamycin) Ifosfamide (Ifex) 10g/m2 Interferon alpha (IFN-alfa, Intron A) 10 million units/m2 Irinotecan (CPT-11, Camptosar) Lomustine (CCNU, CeeNU) Melphalan (L-PAM, Alkeran) 50mg/m2 IV Methotrexate (MTX) 250mg/m2 Oxaliplatin (Eloxatin) 75mg/m2 Temozolomide (Temodar) oral 75mg/m2/d Vinorelbine (Navelbine) oral Gemcitabine (Gemzar) Interferon alpha (IFN-alfa, Intron A) 510 million units/m2 Ixabepilone (Ixempra) Methotrexate (MTX) 50mg/m2 to 250mg/m2 Mitomycin (MTC, Mitozytrex, Mutamycin) Mitoxantrone (DHAD, Novantrone) Paclitaxel (Taxol) Paclitaxel albumin (Abraxane) Pemetrexed (Alimta) Pentostatin (Nipent) Pralatrexate (Folotyn) Romidepsin (Istodax) Thiotepa Topotecan (Hycamtin) IV, oral Mercaptopurine (purinethol) Methotrexate (MTX) 50mg/m2 IV, oral Nelarabine (Arranon) Niltoinib (Tasigna) Ofatumumab (Arzerra) Panitumumab (Vectibix) Pazopanib (Votrient) Pegasparagase (Oncaspar) Peginterferon Rituximab (Rituxan) Sorafenib (Nexavar) Sunitinib (Sutent) Temsirolimus (Torisel) Temozolamide (Temodar) 75mg/m2/d Tretinoin (Vesanoid) Thalidomide (Thalomid) Thioguanine (6-TG,Tabloid) oral Trastuzumab (Herceptin) Valrubicin (Valstar) Vandetanib (Caprelsa) Vinblastine (VLB) Vincristine (VCR) Vinorelbine (Navelbine) IV Vorinostat (Zolinza)

    Moderate Risk (3090% frequency without antiemetics)

    Low Risk (1030% frequency without antiemetics)

    Minimal Risk (<10% frequency without antiemetics)

    NOTES
    *Daily use of antiemetics is not recommended based on clinical experience. Adapted from: 1. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol 2006;24:2932-2947. 2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology; v.1.2012: Antiemesis. Available at: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed August 8, 2012. (Rev. 8/2012)

    You might also like